Truncated N-terminal huntingtin fragment with expanded-polyglutamine (htt552-100Q) suppresses brain-derived neurotrophic factor transcription in astrocytes

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 3, 2012, Pages 249-258

  Wang, Linhui ^a   Lin, Fang ^a   Wang, Jin ^a   Wu, Junchao ^a   Han, Rong ^a   Zhu, Lujia ^a   Zhang, Guoxing ^a   Difiglia, Marian ^b   Qin, Zhenghong ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

astrocytes; brain derived neurotrophic factor; huntingtin; Huntingtons disease; transcription

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HD PROTEIN, HUMAN; HUNTINGTIN PROTEIN, RAT; NERVE PROTEIN; NUCLEAR PROTEIN; PEPTIDE; POLYGLUTAMINE; TRANSCRIPTION FACTOR;

ADENOVIRUS; ANIMAL; ARTICLE; ASTROCYTE; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; NERVE CELL; PROTEIN TERTIARY STRUCTURE; RAT; SPRAGUE DAWLEY RAT;

ADENOVIRIDAE; ANIMALS; ASTROCYTES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; MICROSCOPY, FLUORESCENCE; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS;

RATTUS;

EID: 84863248297     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmr125     Document Type: Article

References (52)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72: 971-983.
2. Borrell-Pagès M, Zala D, Humbert S and Saudou F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 2006, 63: 2642-2660. (Pubitemid 44800717)
3. Sipione S and Cattaneo E. Modeling Huntington's disease in cells, flies and mice. Mol Neurobiol 2001, 23: 21-51. (Pubitemid 32948271)
4. Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK and Bromm M, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 1996, 13: 442-449. (Pubitemid 26256618)
5. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R and McCutcheon K, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998, 273: 9158-9167. (Pubitemid 28176206)
6. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B and Cattaneo E, et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem 2000, 275: 19831-19838. (Pubitemid 30441585)
7. Gafni J and Ellerby LM. Calpain activation in Huntington's disease. J Neurosci 2002, 22: 4842-4849. (Pubitemid 37465599)
8. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR and Ellerby LM. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 2004, 279: 20211-20220. (Pubitemid 38623466)
9. Lunkes A, Lindenberg KS, Ben Haiem L, Weber C, Devys D, Landwehrmeyer GB and Mandel JL, et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 2002, 10: 259-269. (Pubitemid 35007341)
10. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK and Loubser O, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci 2002, 22: 7862-7872. (Pubitemid 35379091)
11. Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW and Hayden MR. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 2001, 68: 313-324. (Pubitemid 32147802)
12. Rigamonti D, Bauer JH, De Fraja C, Conti L, Sipione S, Sciorati C and Clementi E, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000, 20: 3705-3713. (Pubitemid 30266233)
13. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L and MacDonald ME, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293: 493-498. (Pubitemid 32679077)
14. Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, Kaminsky Z and Masone J, et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 1998, 7: 783-790. (Pubitemid 28221240)
15. Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, Zhang T and Kalchman M, et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998, 141: 1097-1105. (Pubitemid 28265605)
16. Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, Mc-Cutcheon K and Singaraja R, et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998, 18: 150-154. (Pubitemid 28082462)
17. Saudou F, Finkbeiner S, Devys D and Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95: 55-66.
18. Wang LH and Qin ZH. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies. Acta Pharmacol Sin 2006, 27: 1287-1302.
19. Murer MG, Yan Q and Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001, 63: 71-124.
20. Ferrer I, Goutan E, Marin C, Rey MJ and Ritalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res 2000, 866: 257-261. (Pubitemid 30313028)
21. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L and Cataudella T, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003, 35: 76-83. (Pubitemid 37048599)
22. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE and Hackam AS, et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 2004, 11: 424-438. (Pubitemid 38489420)
23. Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M and Valenza M, et al. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res 2005, 52: 133-139. (Pubitemid 40828363)
24. Sugars KL and Rubinsztein DC. Transcriptional abnormalities in Huntington disease. Trends Genet 2003, 19: 233-238. (Pubitemid 36511427)
25. Sugars KL, Brown R, Cook LJ, Swartz J and Rubinsztein DC. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J Biol Chem 2004, 279: 4988-4999. (Pubitemid 38199095)
26. Cong SY, Pepers BA, Evert BO, Rubinsztein DC, Roos RA, van Ommen GJ and Dorsman JC. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol Cell Neurosci 2005, 30: 12-23. (Pubitemid 41133336)
27. Takeuchi Y, Miyamoto E and Fukunaga K. Analysis on the promoter region of exon IV brain-derived neurotrophic factor in NG108-15 cells. J Neurochem 2002, 83: 67-79.
28. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM and Mouradian MM, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296: 2238-2243. (Pubitemid 34680312)
29. Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H and Li XJ. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 2002, 22: 1277-1287. (Pubitemid 34150765)
30. Blondel O, Collin C, McCarran WJ, Zhu S, Zamostiano R, Gozes I and Brenneman DE, et al. A glia-derived signal regulating neuronal differentiation. J Neurosci 2000, 20: 8012-8020.
31. Farina C, Aloisi F and Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007, 28: 138-145. (Pubitemid 46283692)
32. Liberto CM, Albrecht PJ, Herx LM, Yong VW and Levison SW. Pro-regenerative properties of cytokineactivated astrocytes. J Neurochem 2004, 89: 1092-1100.
33. Maccioni RB, Munoz JP and Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001, 32: 367-381. (Pubitemid 32918139)
34. Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH and Dickson DW, et al. Expanded polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci 2008, 28: 3277-3290. (Pubitemid 351469331)
35. Wang LH, Lin F, Wu JC and Qin ZH. High efficiency adenovirusmediated expression of truncated N-terminal huntingtin fragment (htt552) in primary rat astrocytes. Acta Biochim Biophys Sin 2009, 41: 325-334.
36. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25: 402-408. (Pubitemid 34164012)
37. Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M and Persson H. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 1993, 10: 475-489. (Pubitemid 23111738)
38. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL and Kazantsev A, et al. Histone deacetylase inhibitors arrest polyglutaminedependent neurodegeneration in Drosophila. Nature 2001, 413: 739-743. (Pubitemid 33009952)
39. Warby SC, Doty CN, Graham RK, Carroll JB, Yang YZ, Singaraja RR and Overall CM, et al. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum Mol Genet 2008, 17: 2390-2404.
40. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G and Pearson J, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125: 1179-1191. (Pubitemid 43866195)
41. Zuccato C and Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007, 81: 294-330. (Pubitemid 46528643)
42. Timmusk T, Palm K, Lendahl U and Metsis M. Brain-derived neurotrophic factor expression in vivo is under the control of neuron-restrictive silencer element. J Biol Chem 1999, 274: 1078-1084. (Pubitemid 29058083)
43. Buckley NJ, Johnson R, Zuccato C, Bithell A and Cattaneo E. The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol Dis 2010, 39: 28-39.
44. McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J and Merry D, et al. CREB binding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000, 9: 2197-2202.
45. Nucifora FC, Jr, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M and Takahashi H, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291: 2423-2428. (Pubitemid 32231807)
46. Yu ZX, Li SH, Nguyen HP and Li XJ. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Mol Genet 2002, 11: 905-914.
47. Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, Glajch KE and DiRocco DP, et al. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiol Dis 2006, 22: 233-241.
48. Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L and Bates GP. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 2001, 8: 807-821. (Pubitemid 33055597)
49. Lievens JC, Rival T, Iche M, Chneiweiss H and Birman S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet 2005, 14: 713-724. (Pubitemid 40309596)
50. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH and Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005, 171: 1001-1012.
51. Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, Donnan GA and Howells DW. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 1999, 19: 1708-1716. (Pubitemid 29094189)
52. Ceccatelli S, Ernfors P, Villar MJ, Persson H and Hökfelt T. Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment. Proc Natl Acad Sci USA 1991, 88: 10352-10356. (Pubitemid 21915833)